The above considering, we hypothesized that RANKL may be positively associated with hepatic steatosis and inflammation and we initiated a non-sponsored clinical trial with denosumab (anti-RANKL antibody) administration to patients with osteoporosis and NAFLD, which is currently ongoing (clinicaltrials.gov identifier: NCT05493761) [50]. Here, TNFSF11 is linked to metabolic dysfunction-associated steatotic liver disease.